Stem cells and their role in pituitary tumorigenesis by Carreno, G et al.
 1 
Stem cells and their role in pituitary tumorigenesis    
 
Gabriela Carreno*, Jose Mario Gonzalez-Meljem*, Scott Haston*, Juan Pedro Martinez-
Barberaa 
Developmental Biology and Cancer Program, Birth Defects Research Centre, Institute of Child 
Health, University College London. London, United Kingdom    
 
*Authors contributed equally to this work 
a Corresponding author: Juan Pedro Martinez-Barbera, Developmental Biology and Cancer 
Program, Birth Defects Research Centre, Institute of Child Health, University College London. 
London, WC1N1EH, United Kingdom. Telephone: 44-207-905-2821; Fax: 44-207-831-4366; 
e-mail: j.martinez-barbera@ucl.ac.uk.    
    
 
Keywords: pituitary; stem cell; cancer stem cell; pituitary adenoma; adamantinomatous 
craniopharyngioma    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Abstract 
The presence of adult pituitary stem cells (PSCs) has been described in murine systems 
by comprehensive cellular profiling and genetic lineage tracing experiments. PSCs are thought 
to maintain multipotent capacity throughout life and give rise to all hormone-producing cell 
lineages, playing a role in pituitary gland homeostasis. Additionally, PSCs have been proposed 
to play a role in pituitary tumorigenesis, in both adenomas and adamantinomatous 
craniopharyngiomas. In this manuscript, we discuss the different approaches used to 
demonstrate the presence of PSCs in the murine adult pituitary, from marker analyses to genetic 
tracing. In addition, we review the published literature suggesting the existence of tumor stem 
cells in mouse and human pituitary tumors. Finally, we discuss the potential role of PSCs in 
pituitary tumorigenesis in the context of current models of carcinogenesis and present evidence 
showing that in contrast to pituitary adenoma, which follows a classical cancer stem cell 
paradigm, a novel mechanism has been revealed for paracrine, non-cell autonomous tumor 
initiation in adamantinomatous craniopharyngioma, a benign but clinically aggressive pediatric 
tumor.  
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Introduction 
The pituitary gland is a master endocrine organ that orchestrates the release of several 
hormones as a consequence of hypothalamic and peripheral organ signals (Denef, 2008). The 
finely tuned release of these hormones is essential for many physiological processes such as 
growth, metabolism and reproduction (Drouin, 2011). During recent years a substantial amount 
of work has revealed the existence of pituitary stem cells (PSCs), which reside in the embryonic 
and postnatal pituitary (Castinetti et al., 2011; Vankelecom and Chen, 2013). These 
undifferentiated progenitor/stem cells have the capability to commit and give rise to all three 
main pituitary hormone-producing cell lineages (through the activation of essential 
transcription factors: PIT1, TPit and SF1) and ultimately differentiate into the mature hormone-
producing populations (Dasen and Rosenfeld, 2001; Zhu et al., 2007). These PSCs have been 
shown to contribute to organ homeostasis and tumorigenesis (Andoniadou et al., 2013; Rizzoti 
et al., 2013).  
 
In this concise review, we aim to address the growing body of evidence that suggests 
the importance of PSC in the formation and progression of pituitary tumors. Specifically, we 
will focus on Adenomas and Adamantinomatous Craniopharyngioma. The regulation of the 
pituitary stem cells and its signaling pathways is the subject of a separate review in this issue 
(S. Camper and MI. Perez-Millan, this Issue).         
 
The properties and identity of pituitary stem cells  
 
Stem cells (SCs) are characterized by the capacity to self-renew and to divide 
asymmetrically giving rise to progenitors with multipotent differentiation capability. These 
progenitors can either terminally differentiate or become transit-amplifying cells which further 
proliferate in order to sustain a pool of undifferentiated tissue-specific progenitors (Hsu et al., 
2014). SCs are therefore able to maintain and replenish the pool of tissue-specific progenitor 
cells which are essential for embryonic development and plastic tissue adaptation, such as that 
occurring during homeostatic turnover or in regeneration after injury (Patel et al., 2013; van Es 
et al., 2012).   
 
SCs can be experimentally characterized by the expression of defined stem cell-
associated factors (e.g. SOX2, NANOG, OCT4, SCA1 and CD44), their in-vitro clonogenic 
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potential or the identification of a side population by flow cytometry (Goodell et al., 1996; 
Lepore et al., 2005; Puck and Marcus, 1956). A decade of research has provided convincing 
evidence that adult PSCs exist. Firstly, it was shown that pituitary cells grown in stem cell-
promoting media form adherent colonies, which actively uptake the fluorescent dipeptide β-
Ala-Lys-Nε-AMCA and express S100β, both markers of pituitary folliculostellate cells (FS) 
(Lepore et al., 2005). These adherent colonies were also able to differentiate into hormone 
producing cells, indicating their multipotent capacity. Another study reported that non-
adherent sphere colonies, referred to as “pituispheres”, could be grown in clonal conditions 
and were shown to express stem cell-associated markers such as OCT4 and NANOG. This 
pituitary cell population had the capacity to efflux verapamil-sensitive Hoechst dye, which 
allowed the identification of a side population with SC properties by flow cytometry (Chen et 
al., 2005). Cells within the side population expressed Stem Cell Antigen 1 (SCA1), showed 
increased expression of SOX2, SOX9, CD44 and CD133, as well as the activation of 
developmental pathways essential for stem cell homeostasis and embryogenesis (i.e. Notch, 
Wnt and Shh) (Chen et al., 2009).     
 
Since the first characterization of PSC populations, several other cell populations have 
been identified with in-vitro clonogenic potential such as those expressing NESTIN, PROP1, 
PRX1/2, GFRα2 or CXCR4 (Garcia-Lavandeira et al., 2009; Gleiberman et al., 2008; Higuchi 
et al., 2014; Horiguchi et al., 2012; Nomura et al., 2009; Rizzoti et al., 2013). NESTIN has 
been shown to have overlapping expression with SOX2+ cells in the marginal zone (MZ) of 
the anterior pituitary (AP) and in pituispheres. However, expression of NESTIN is not 
restricted to PSCs and is heterogeneous, including non-hormonal pituitary cell types 
(Krylyshkina et al., 2005; Vankelecom, 2007). Expression of PROP1, an essential embryonic 
pituitary transcription factor, has been confirmed in adult PSCs (Garcia-Lavandeira et al., 
2009; Yoshida et al., 2009). Additionally, it has been shown that expression of 
SOX2+/PROP1+ must be downregulated postnatally for hormonal cell differentiation (Chen 
et al., 2009; Fauquier et al., 2008; Gremeaux et al., 2012; Yoshida et al., 2009). Recently, it 
was also shown that PROP1 expression is required to maintain a normal pool of PSCs both 
embryonically and postnatally by orchestrating an EMT-like process (Pérez Millán et al., 
2016). PRX1 and 2 are paired related homeodomain proteins that have been identified in the 
PSC side populations, including a population of SOX2+/PROP1+ periluminal embryonic 
pituitary cells (Susa et al., 2012), and it has been suggested that expression of PRX1/2 is 
essential for the maintenance and proliferation Rathke’s pouch progenitor cells up until 
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differentiation (Vankelecom, 2010). The chemokine receptor CXCR4 has been found to be 
expressed in FS cells and in other cells of the AP (Barbieri et al., 2007; Horiguchi et al., 2012). 
In addition, CXCR4 and its ligand CXCL12 were identified in the stem cell-enriched side 
population of the mouse pituitary gland (Vankelecom, 2010). The well-known chemotactic and 
trophic properties of CXCR4 and its ligand suggest a possible role for migration and 
maintenance of PSCs (Barbieri et al., 2007). Finally, a population expressing GFRα2, RET and 
PROP1 (referred to as “GPS” cells), as well as other SC markers, has been proposed to form 
part of a SC niche located in the MZ of the pituitary lumen and it has been suggested they may 
play a role in PSC regulation, including cell survival or structural guidance of these cells 
(Garcia-Lavandeira et al., 2009). This putative SC population was identified in both human 
and mouse pituitaries and expresses progenitor markers SOX2, SOX9 and OCT4. Half of the 
GPS population also expressed S100β. Additionally, when GFRα2+ cells were isolated from 
mouse pituitaries they could be cultured as spheres and could be differentiated into hormone-
producing cell types. Furthermore, an appealing proposal involving the GPS population was 
recently introduced by Garcia-Lavendeira et al., and concerns a mechanism for the regulation 
of pituitary cell turnover (a largely unexplored subject) through the apoptosis of differentiated 
cell types by the RET/Pit-1/Arf/p53 pathway (Garcia-Lavandeira et al., 2015).  
 
SOX2 expression has been shown to be exclusively expressed in both adherent and 
non-adherent PSC colonies in clonal culture (Andoniadou et al., 2012; Fauquier et al., 2008). 
SOX2 is a pluripotency-associated factor expressed in embryonic stem cells, induced 
pluripotent cells and shown to be important for the maintenance of stem cells in various adult 
tissues.  A subset of SOX2 PSCs of the postnatal AP resides in the MZ and are thought to be 
part of the presumptive progenitor/stem cell niche. SOX2+ cells are also expressed throughout 
the AP parenchyma, where SOX2 expression does not overlap with differentiated hormonal 
cells. However, only a small proportion of postnatal SOX2+ cells retain self-renewing 
clonogenic potential when sorted and maintained in clonal culture (2.5-5%) (Andoniadou et 
al., 2013). This could suggest that not all SOX2+ cells of the AP retain stem cell capacity. 
Furthermore, lineage tracing of SOX2+ cells in the postnatal AP revealed their long-term 
persistence and multipotent differentiation capability, as they were shown to give rise to all AP 
hormone-producing cell types throughout life (Andoniadou et al., 2013; Rizzoti et al., 2013).  
Interestingly, SOX2 expression mostly overlaps with SOX9, and partially overlaps with S100β 
in the AP marginal zone, while it was shown that sorted S100β+ cells possess increased 
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clonogenic potential (Rizzoti et al., 2013). Therefore, current evidence suggests 
SOX2+/S100β+ cells represent a type of adult PSCs.  
Finally, there is evidence supporting the existence of PSCs in humans. In one study, 
isolation and culture of pituispheres derived from 5 patients after autopsy was reported. The 
resulting pituispheres were shown to express NESTIN, pituitary-specific markers LHX3 and 
PITX2 after several passages, as well as expressing all six pituitary hormones (Weiss et al., 
2009). In another study, authors identified a GPS population similar to that shown to exist in 
mouse pituitaries. This population was located in the MZ and showed the expression of 
stemness-associated factors SOX2, SOX9, OCT4, KLF4 and GFRA3 (Garcia-Lavandeira et 
al., 2011)   
 
In summary, there has been extensive characterization of candidate PSC populations 
which express stem cell associated markers and display stem cell related features. However, 
“stemness” marker expression alone, is not sufficient for defining a SC population. For 
example, S100β+ cells appear to be a heterogeneous population encompassing folliculostellate 
cells and also subsets of stem cells, committed progenitors and pituicytes of the postnatal 
pituitary (Sato et al., 2005; Soji et al., 1997; Yoshida et al., 2016). Furthermore, expression of 
NESTIN is not restricted to PSCs, but has been shown to be expressed in pericytes and non-
hormonal pituitary cell types (Galichet et al., 2010; Krylyshkina et al., 2005; Vankelecom, 
2007). Therefore, further experiments are needed in order to properly assert putative S100+ 
and NESTIN+ subsets as PSCs. Ultimately, long-term lineage tracing in vivo of these 
populations would demonstrate their persistence and their ability to give rise to differentiated 
progeny.  
 
Cancer stem cells and the cancer stem cell model 
 
Similar to the presence of tissue specific stem cells, experimental evidence has revealed 
the presence of multipotent cells thought to continuously propagate cancer cells within tumors 
(Kreso and Dick, 2014; Nakanishi et al., 2013; Schepers et al., 2012; Zomer et al., 2013). These 
cancer stem cells (CSCs) possess many similarities to normal tissue specific stem cells, as they 
retain the capability to self-renew, give rise to cancer cell progenitors with multipotent 
differentiation potential, can be slow-cycling/quiescent (e.g. neural stem cells) or divide rapidly 
(e.g. crypt stem cells), and are resistant to chemotherapeutics and radiotherapy (Abdullah and 
Chow, 2013; Stange and Clevers, 2013). CSCs are of great clinical relevance as they are 
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thought to drive tumor cell propagation and give rise to the bulk of the tumor mass cell-
autonomously. Together with their persistent self-renewal and resilience to chemo and 
radiotherapy, CSCs are thought to be responsible for driving tumor recurrence and progression 
after conventional treatment. Therefore, cancer therapy should aim to target both the bulk of 
the proliferating tumor mass, and the small proportion of tumor-driving CSCs that may persist 
after common cancer treatments.  
 
 In some tumors, it has been shown that normal tissue specific SCs can be transformed 
into oncogenic CSCs (Nakanishi et al., 2013; Schepers et al., 2012; Zomer et al., 2013), while 
some cancers have been found to be driven by oncogenic transformed progenitor or 
differentiated cell types (Clevers, 2011; Valent et al., 2012). Irrespectively of the cell of origin 
(i.e. the cell sustaining the first oncogenic hit), the prevalent view is that at any given point in 
cancer progression, there is only a subset of cells (CSCs) capable of self-renewal and with the 
proliferative potential necessary to give rise to the bulk-mass of the tumor (Kreso and Dick, 
2014; Visvader and Lindeman, 2008).     
 
CSCs were first isolated from leukemia, however their presence was later demonstrated 
in multiple types of solid tumors (Al-Hajj et al., 2003; Guo et al., 2008; Nguyen et al., 2012; 
Visvader and Lindeman, 2008). These studies helped establish common features shared by 
CSCs that can be useful for their identification, such as the expression of stem cell-associated 
markers. However, the accepted definition of CSCs requires their identification in situ by 
lineage tracing and/or serial orthotropic transplantation, most commonly in immuno-
compromised hosts (Alison et al., 2008; Clarke and Fuller, 2006; Clevers, 2011). This allows 
clonal tracking in serially transplanted hosts, as daughter tumors will phenocopy the primary 
tumor and indicate the presence of a CSC able to propagate the tumor.  
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Cancer stem cells in pituitary adenomas 
 
Overview of pituitary adenomas and their pathogenesis 
 
Pituitary adenomas are among the most common intracranial neoplasms (up to 15%) 
and cross-sectional studies have found a prevalence of around 90 cases per 100,000 inhabitants, 
with the vast majority being adults over 30 years old (Karavitaki, 2012). The occurrence of 
true pituitary carcinomas is extremely rare, meaning that most cases are benign in terms of 
their histopathological features (Shlomo Melmed, 2011). However, their clinical management 
can be complicated due to hormone hypersecretion (Zhou et al., 2015) or the development of 
aggressive behavior characterized by resistance to treatment, high proliferative index, 
recurrence and invasion of nearby tissues (Chatzellis et al., 2015; Del Basso De Caro et al., 
2016; Di Leva et al., 2014).  
 
Adenomas can be classified as either: 1) hormone secreting adenomas, as defined by 
the presence of one or more hyperplastic pituitary endocrine populations (lactotrophs, 
gonadotrophs, somatotrophs, corticotrophs and thyrotrophs); or 2) non-functional adenomas, 
which are thought to be mainly derived from gonadotroph cells (Melmed, 2015). 
 
Despite their significant prevalence in the population, the etiology and pathogenesis of 
pituitary adenomas have only recently begun to be addressed from a molecular point of view. 
Some groups have provided insights into the clonal and mutational landscape of these tumors, 
information which could be used for efficient patient risk stratification and appropriate therapy 
selection. 
 
The most accepted view is that the majority of the pituitary adenomas are monoclonal 
in origin, as determined by X-chromosome inactivation assays (Alexander et al., 1990; Herman 
et al., 1990; Ma et al., 2002; Schulte et al., 1991). However, this idea has been contested by 
studies were X-chromosome inactivation and Loss of Heterozygosity (LOH) analysis were 
combined and showed different clonal origins in adenomas before and after recurrence 
(Clayton et al., 2000), as well as in between primary tumors and distant metastases in malignant 
adenomas (Buch et al., 2002; Clayton and Farrell, 2006). These discrepancies could be 
attributed to tissue sampling variability but also suggest that more than one cell population with 
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tumorigenic capacity can exist at distinct points during the tumorigenic process, at least in a 
proportion of pituitary adenomas.  
 
A wealth of evidence has recently accumulated regarding key dysregulated genes and 
mutations relevant to the pathogenesis of pituitary adenomas in both mice and humans 
(Gadelha et al., 2013; Lines et al., 2016). From this list, the aberrant expression of genes 
including: PTTG, RB, CDKN1A, CDKN2A and CYCLINS A1, B1, B2, E1 and D1; makes cell 
cycle dysregulation stand out as a cellular process commonly altered in pituitary adenomas 
(Aflorei and Korbonits, 2014). However, the true significance of associating pituitary adenoma 
pathogenesis with any mutations and/or dysregulated pathways can only be understood when 
these are studied under a hypothesis-driven theory of carcinogenesis, such as the cancer stem 
cell model (e.g. are these genetic and cellular alterations occurring in the cells responsible for 
feeding tumor growth?).   
 
The identification of cancer stem cells isolated from pituitary adenomas 
 
Evidence supporting the existence of cancer stem cells in tumors and leading to the 
development of the CSC model has existed for more than two decades now and continues to 
increase (Beck and Blanpain, 2013; Kreso and Dick, 2014). However, the existence of CSCs 
in pituitary adenomas has only recently begun to be investigated. 
 
Xu et al. reported for the first time the isolation of tumor cells from human somatotroph 
and non-functioning adenomas which fulfilled several characteristics of CSCs (Xu et al., 2009). 
When cultured in stem cell promoting media, the isolated cells formed floating sphere colonies 
and expressed well-known stem cell markers such as: OCT4, CD133 and NESTIN. These 
sphere colonies could be subcloned in culture, expressed pituitary-specific genes like CGA 
(encoding alpha GSU) and PIT1, and could be differentiated into pituitary hormone expressing 
cells in culture. Importantly, these cells could be serially transplanted into mice and gave rise 
to pituitary-hormone producing tumors. A second independent study reported similar results 
where sphere colonies derived from pituitary adenomas also expressed CD133 and NESTIN in 
culture and gave rise to slow-growing, synaptophysin-positive tumors after subcutaneous 
xenotransplantation (Chen et al., 2014). 
 
 10 
Another study reported the identification of tumor cells with a side population profile 
present in a large cohort of human pituitary adenomas (Mertens et al., 2015). Gene expression 
profiling of this tumor side population (TSP) revealed the expression of CSC-related genes 
CD44, CXCR4, KIT, KLF4 and NESTIN. The authors noted that the TSP displayed upregulated 
expression of genes related to epithelial-to-mesenchymal transition (EMT), mesenchymal 
identity, and an endothelial phenotype, suggesting the presence of hematopoietic progenitors. 
After depleting the side population from endothelial and immune cell populations 
(CD31+/CD45+), the authors found increased expression of EMT, stemness, mesenchymal and 
angiogenesis genes in the purified side population (pSP). These pSP cells expressed stem cell 
markers SOX2 and NESTIN, formed pituispheres which could be serially passaged and that 
gave rise to hormone expressing cells corresponding to the adenoma type they were isolated 
from. Although tumor xenografts could not be achieved in this case, the authors identified a 
pSP in an established adenoma cell line and demonstrated they possessed increased 
tumorigenic capacity compared to the main population when injected into SCID mice. Worth 
noting in this study, chemical inhibition of the chemokine receptor CXCR4 lead to decreased 
tumor cell proliferation and viability and a significant reduction in xenograft tumor growth. 
CXCR4 is a well-known CSC marker in other tumors (Fujita et al., 2015; Hermann et al., 2007; 
Jung et al., 2013; Trautmann et al., 2014; Würth et al., 2014) and the importance of CXCR4 
signaling in pituitary adenomas has been suggested by several studies involving human tumors 
and adenoma cell lines (Barbieri et al., 2014). The findings by Mertens et al. suggest that further 
understanding of the role of CXCR4 in pituitary adenoma pathogenesis and adenoma CSCs 
can potentially lead to the development of novel therapeutic strategies for these tumors.  
 
A different cell population with SC-like characteristics in GH-secreting and non-
functioning pituitary adenomas has also been described (Orciani et al., 2015). By using an 
adherent cell culture protocol, researchers isolated progenitor mesenchymal cells (PMCs) that 
showed increased expression of classic pluripotency factors OCT4, NANOG, KLF4 and 
SOX2. However, these cells also fulfilled the expression profile of surface markers that defines 
mesenchymal stem cells (MSCs). These PMCs could give rise to osteogenic, lipogenic and 
chondrogenic lineages and lacked expression of pituitary progenitor genes PITX2, PIT1 and 
PROP1. Moreover, a CD133+ fraction was found to possess increased migratory capabilities 
in trans-well migration assays. Although the authors do not directly address the capability of 
the PMCs to form pituitary hormone cells, their results suggest the existence of more than one 
cell population with CSC characteristics within tumors, but with totally different identities and 
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functions. They also indicate care must be taken in future studies addressing CSC biology as 
the expression of pluripotency factors and cell surface markers can be shared by unrelated 
CSCs populations. 
 
Recently, a study reported the derivation of cell lines with SC-like characteristics from 
several human pituitary adenomas, either through selection in SC-permissive media or by 
sorting for CD133 expression (Würth et al., 2016). The authors reported isolation of SC-like 
cells and successful culture establishment from 68% of the adenomas. These cells could be 
grown as pituispheres, formed secondary spheres upon dissociation and also expressed SC 
markers SOX2, OCT4, NESTIN, CD133 and CXCR4. When maintained in stem cell-
permissive medium, these cell lines retained their proliferative potential for up to 2 months and 
could be differentiated into hormone-secreting cells. However, cell-line xenografts in NOD-
SCID mice did not lead to tumor growth. This is in contrast to other studies (described above) 
which reported successful tumor growth from xenografted pituitary adenoma CSCs (Chen et 
al., 2014; Xu et al., 2009). Nonetheless, it must be noted that in these studies tumor growth was 
achieved in relatively small numbers (one and two tumors, respectively). Additionally, Mertens 
et al. also reported absence of tumor growth with several adenoma samples and different 
xenograft approaches (Mertens et al., 2015). These discrepancies could be due to 
methodological differences related to either the use of in vitro culture of CSCs prior to 
transplantation, the heterogeneity of different tumor samples used in these studies (e.g. 
somatotropinomas and non-functioning adenomas) or distinct CSC populations with divergent 
growth dynamics. Investigations using larger cohorts of human samples will be necessary to 
determine the presence of a serially propagating cell tumorigenic cells able to recapitulate the 
original tumor. Additionally, further work using genetically-engineered mouse models of 
pituitary adenomas will provide genetic evidence of the existence of CSC populations, in 
agreement with the CSC paradigm. 
 
So far there is only one report of CSC isolation from murine pituitary adenomas. 
Researchers derived cells from intermediate lobe tumors formed spontaneously in Rb+/- mice 
and these cells formed pituispheres, which could be serially passaged, even after dissociation. 
These spheres additionally expressed stem cell related factors SOX2, NESTIN and CD133 and 
could be differentiated to all hormone producing cell types. They further identified a SCA1+ 
tumor cell subpopulation which demonstrated increased sphere forming capacity, enriched 
stem cell marker expression and importantly, possessed a significant increase in tumor forming 
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potential compared to SCA1-negative cultured cells when transplanted into NOD-SCID mice 
(Donangelo et al., 2014). 
 
The discovery of pituitary adenoma CSCs as well as the evidence for the monoclonal 
origin of these tumors falls in line with the CSC paradigm. However, further research using 
lineage tracing and transplantation studies is required in order to strongly assert the relationship 
between the cells that carry the first oncogenic hit (tumor initiating cells) and the CSCs that 
feed tumor growth at any given point. 
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Non-cell autonomous involvement of stem cells in the development 
of adamantinomatous craniopharyngioma 
 
Investigation of another pituitary tumor type known as adamantinomatous 
craniopharyngioma (ACP) has uncovered that mutated PSCs can promote tumorigenesis in a 
non-cell autonomous manner, in contrast to the classical CSC paradigm. ACPs are benign 
tumors of the sellar region that aggressively infiltrate into surrounding structures, such as the 
brain, optic tracts and associated vasculature (Müller, 2010). The disease most commonly 
affects children, representing the most common pediatric tumor of the pituitary gland in this 
age group (Müller, 2014). 
 
Molecular studies have revealed that mutations in the CTNNB1 gene, which encodes β-
catenin, have been observed in the majority of human ACP samples (Buslei et al., 2005). The 
identified mutations are predicted to result in the stabilization of β-catenin by interfering with 
the ability of the protein to be targeted for proteasomal degradation. This stabilization results 
in accumulation of the protein and subsequent activation of the Wnt/β-catenin signaling 
pathway (Buslei et al., 2007). In corroboration, immunohistochemical analysis of human ACP 
samples reveals the presence of populations of cell clusters which accumulate 
nucleocytoplasmic β-catenin (Figure 1a), indicative of Wnt pathway activation in these cells 
(Hofmann et al., 2006). These cell clusters are a unique feature of ACP, relative to other 
pituitary tumor types, and are recognized as a hallmark of the disease (Hölsken et al., 2013). 
Analysis of human ACPs for the presence of CSC populations has not been performed. Some 
studies have reported the expression of stem cell markers in human ACPs, such as SOX2, 
SOX9, OCT4, GFRa3, RET, KLF4 and CD133 (Garcia-Lavandeira et al., 2015, 2011; Gaston-
Massuet et al., 2011; Hölsken et al., 2013). However, functional characterization of these cell 
populations has not yet been performed. 
 
A study using a genetically-engineered mouse (GEM) model (Hesx1Cre/+; 
Ctnnb1lox(ex3)/+) demonstrate that the expression of a degradation resistant form of β-catenin in 
the precursor of the pituitary gland, Rathke's pouch (RP), is sufficient to drive the formations 
of tumors similar to human ACP (Andoniadou et al., 2012). RP is an embryonic structure that 
gives rise to the anterior pituitary and possesses undifferentiated progenitor cells that are able 
to transiently self-renew and generate all AP hormone-producing cells. Similar to the situation 
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observed in human ACP, this GEM model demonstrates the characteristic β-catenin 
nucleocytoplasmic-accumulating cells clusters (Figure 1b). Cells possessing self-renewing 
properties and the ability to differentiate have been observed in this GEM model of ACP 
(Andoniadou et al., 2012). The murine tumorigenic pituitaries contain up to three times more 
clonogenic cells in vitro than the pituitary of control mice, suggesting an expansion of a stem 
cell compartment. Molecular analysis of these cells demonstrates expression of the stem cell 
markers SOX2 and NESTIN, with absence of pituitary differentiation markers. Furthermore, 
these cells have a proliferation rate that is 1.7-fold higher than normal PSCs cultured from wild 
type pituitaries. The ability of these putative CSC from mouse ACPs to generate tumors 
following transplantation remains to be elucidated. 
 
A further GEM model has been generated (Sox2CreERT2/+;Ctnnb1lox(ex3)/+), which also 
give rise to tumors resembling some aspects human ACP. For instance, cell clusters showing 
β-catenin nucleocytoplasmic-accumulation are present and the tumors are synaptophysin- 
negative (Andoniadou et al., 2013) (Figure 1c). Genetic linage tracing through recombination-
mediated activation of a yellow fluorescent protein (YFP) reporter in SOX2+ cells allowed for 
the identification of daughter cells derived from these oncogene-targeted SOX2+ PSCs. This 
analysis revealed that the β-catenin-accumulating cell clusters are derived from SOX2+ PSCs, 
however, the tumors lack expression of the YFP reporter, suggesting a different cell-of-
origin. Intriguingly, this result indicates that the oncogene targeted SOX2+ PSCs do not cell-
autonomously give rise to the tumor mass but instead generate these tumors from non-targeted 
cells in a paracrine manner (Andoniadou et al., 2013). Thus, paracrine tumorigenesis is distinct 
from the CSC model, as the original mutation-sustaining cell is not the clonal cell of origin 
from which the tumor develops. 
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Figure 1. Nucleo-cytoplasmic accumulating β-catenin clusters are found in human 
adamantinomatous craniopharyngioma (ACP) and murine models for ACP.  
(a) Immunofluorescent staining in human ACP showing the nucleo-cytoplasmic accumulation 
of β-catenin in cell groups known as “clusters” (arrows), a defining characteristic of these 
tumors. (b) Expression of oncogenic β-catenin in embryonic pituitary progenitors also leads to 
the formation of clusters in Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos. An 18.5 dpc specimen is 
shown. (c) Clusters also form upon inducible expression of oncogenic β-catenin in adult 
pituitary stem cells of Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice. 16-week post-tamoxifen induction 
shown. Scale bars: 100 μm.  
 
It may be possible that the paracrine activities of the oncogene-targeted SOX2+ PSCs 
induce the formation of CSC that cell-autonomously drive tumor formation. Conceivably, these 
cell clusters act as signaling centers and promote tumorigenesis either directly or indirectly 
through cell-cell signaling interactions or microenvironmental changes (Andoniadou et al., 
2013). In corroboration of this concept, transcriptomic profiling of β-catenin-accumulating 
cell clusters reveals the expression of a plethora of growth factors, chemokines and cytokines, 
which appear conserved between mouse models and human ACP (Andoniadou et al., 2012). 
Further studies have revealed a role for several cytokines and growth factors in normal pituitary 
physiology and in pituitary adenomas (Arzt et al., 1999; Graciarena et al., 2004; Uhrbom et al., 
1998).  
 
In support of this emerging model of paracrine tumorigenesis it has been demonstrated 
that excessive levels of mitogenic signals can result in tumor formation in other systems. The 
overexpression of platelet-derived growth factor (PDGF) in neural progenitor cells results in 
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the formation of neural tumors, which appear similar to human glioma. Human TGF-alpha 
secretion by rat fibroblasts promotes tumor formation in nude mice (Rogelj et al., 1988). 
Similarly, basic fibroblast growth factor (bFGF) can induce the transformation of non-
transformed cells (Arwert et al., 2010). Evidence for non-cell autonomous tumor or cancer 
formation has also been provided by GEM models in the skin, liver and hematopoietic system. 
Skin polyps containing predominantly wild type cells can be generated by targeting the 
epidermis with a constitutively active form of MEK1, which results in activation of the 
mitogen-activated protein kinase (MAPK) pathway (Nicolas et al., 2003). Further to this, 
epidermal or hair follicle deletion of Notch1 results in the formation of skin tumors 
which possess wild type Notch1 (Deschene et al., 2014). Deletion of p53 in hepatic stellate 
cells induces the formation of epithelial tumors that are primarily wild type for p53 (Lujambio 
et al., 2013). The most striking example of paracrine transformation in vivo is found in a GEM 
model of leukemia. In this system, the expression of a degradation-resistant form of β-catenin 
in osteoblast precursors is capable of transforming hematopoietic stem cells (HSCs) and give 
rise to myeloid leukemia (AML). This result can also be achieved though the transplantation of 
wild type bone marrow to lethally irradiated mice which carry osteoblasts targeted with 
oncogenic β-catenin. Further to this, the serial transplantation of these leukemogenic wild type 
HSC progenitors, but not non-HSC populations, is capable of giving rise to AML in wild type 
host mice. This suggests that the HSCs have been induced to become CSCs due to the non-cell 
autonomous activities of the oncogenic β-Catenin targeted osteoblasts (Kode et al., 2014). 
 
Therefore, the formation of ACP appears to be dependent on PSCs harboring an 
oncogenic mutation in β-catenin. However, in contrast to the classical CSC paradigm these 
mutated somatic stem cells do not cell-autonomously generate the ACP tumor but instead result 
in the paracrine transformation of a distinct cell type. Such paracrine interactions may favor 
the emergence of CSC populations that clonally contribute to tumor formation in the pituitary. 
As ACPs are relatively slow-growing benign tumors, these studies have provided insight into 
the initial steps of tumor formation, which are mostly over-looked in cancer biology. Therefore, 
paracrine interactions between SCs and tumor-initiating cells during the initial stages of 
tumorigenesis could be applicable to many other types of cancer (besides those known for their 
benign nature) before tumor cells become self-sufficient (Figure 2).  
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Figure 2. Comparison of different models of tumourigenesis.  
(a) The cancer stem cell (CSC) model establishes that an original cell, being either a progenitor, 
committed or differentiated cell type, is initially transformed by an oncogenic stimulus. This 
cell’s lineage can be traced using a genetic reporter strategy (fluorescent YFP labelling in this 
example, depicted in green). All the descendants from the original cell carry the oncogenic 
mutation and express YFP. At some point a YFP+ descendant cell acquires a CSC phenotype 
(green/red cell) which allows it to self-renew and divide asymmetrically giving rise to 
differentiated tumor cells (green/purple cell), which form the bulk mass of a YFP+ tumor. (b) 
The paracrine model of tumourigenesis proposed by Andoniadou et al. states that expression 
of oncogenic β-catenin in SOX2+ adult pituitary stem cells leads to non-cell autonomous tumor 
formation. After a burst of proliferation, targeted cells (also labelled by YFP) form nucleo-
cytoplasmic accumulating β-catenin clusters. These clusters secrete a plethora of pro-
oncogenic factors which induce the paracrine transformation of a neighboring cell-of-origin, 
giving rise to a YFP- tumor. Further maintenance or progression of YFP- tumors might also be 
aided by continuous SASP signaling from the β-catenin clusters.  
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Concluding Remarks 
 
In conclusion, increasing amount of evidence over the years in mouse and human has 
provided solid support for the theory that CSCs play a role in pituitary tumorigenesis. 
Experimental evidence has shown that the classical CSC paradigm model applies to human 
and mouse pituitary adenomas, in which the oncogenically transformed CSC gives rise to the 
tumor clonally. Interestingly, analysis of a mouse model for adamantinomatous 
craniopharyngioma has revealed a critical role for paracrine signaling in non-cell autonomous 
tumor initiation. 
The studies covered in this review highlight the biological and functional heterogeneity 
of both PSCs and CSCs in pituitary tumor pathogenesis. Therefore, a better understanding these 
cell populations together with the mechanisms and pathways involved in the initiation and 
progression of tumorigenesis will be crucial for the advancement of the field of pituitary cancer 
biology. Furthermore, these advances could lead to the identification of diagnostic markers, 
translating into early detection of these tumors and more effective treatment in human patients.  
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